Session » Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Date: Monday, November 9, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1942

Analysis of Vasculitis Patterns in Patients with Giant Cell Arteritis Compared to Patients with Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 1923

Angiographic Progression of Disease in Large-Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 1937

Aortic Aneurysm in Giant Cell Arteritis: A Nationwide Analysis

9:00AM-11:00AM: Abstract Number: 1922

Association of Leukocyte Populations in Peripheral Blood and Arterial Wall Inflammation Assessed by FDG-PET in Takayasu’s Arteritis and Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1945

Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1939

Definitions and Reliability Assessment of Chronic Ultrasound Lesions of the Axillary Artery in Giant Cell Arteritis: A Study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group

9:00AM-11:00AM: Abstract Number: 1931

Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1919

Efficacy & Safety of Tocilizumab in Giant Cell Arteritis: A Single Centre NHS Experience Using Imaging (Ultrasound and PET CT) as a Diagnostic and Monitoring Tool

9:00AM-11:00AM: Abstract Number: 1918

Efficacy and Safety of Methotrexate in Giant Cell Arteritis: Results from a Bicentric Portuguese Cohort Study

9:00AM-11:00AM: Abstract Number: 1920

Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment

9:00AM-11:00AM: Abstract Number: 1926

Efficacy of Adjunctive Methotrexate in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Subanalysis of a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 1946

Fast-Track Giant Cell Arteritis Clinic Experience in the United States

9:00AM-11:00AM: Abstract Number: 1932

Giant Cell Arteritis – the Relationship Between the Extensiveness of Vasculitis and the Clinical Presentation

9:00AM-11:00AM: Abstract Number: 1940

In Newly Diagnosed Giant Cell Arteritis in a Real Life Setting Relapses Are Seen in More Than a Third of Patients – and Despite Faster Early Reduction High Cumulative Glucocorticoid Doses Are Reached

9:00AM-11:00AM: Abstract Number: 1924

Low Immunogenicity in Patients with Giant Cell Arteritis Treated with Tocilizumab: 3-Year Results from the Randomized Controlled Portion and the Open-Label Follow-Up of a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 1921

Ongoing Vascular 18F-FDG Uptake Despite Clinical Remission in Patients Receiving Tocilizumab for Large Vessel Vasculitis-Giant Cell Arteritis: Single Universitary Center Experience of 30 Patients

9:00AM-11:00AM: Abstract Number: 1941

Outcome of Giant Cell Arteritis Patients Who Were Primarily Admitted for Venous Thromboembolism Events

9:00AM-11:00AM: Abstract Number: 1935

Predictors of Early Mortality for Giant Cell Arteritis at the Time of Diagnosis

9:00AM-11:00AM: Abstract Number: 1944

Predictors of Visual Loss and Cerebrovascular Accidents in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1936

Prospective Analysis of Flow Velocity of the Central Retinal Artery in Newly Diagnosed Patients with Giant Cell Arteritis with Visual Symptoms and Controls

9:00AM-11:00AM: Abstract Number: 1928

Quantitative Ultrasound of Temporal, Axillary and Subclavian Arteries to Monitor Tocilizumab Treatment in Patients with Newly Diagnosed Giant Cell Arteritis: A 24 Week Analysis

9:00AM-11:00AM: Abstract Number: 1947

Risk Factors for Anxiety and Depression in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1938

Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1933

Small Vessel Vasculitis Surrounding a Preserved Temporal Artery: Search for Tissue Biomarkers with Potential Diagnostic Value

9:00AM-11:00AM: Abstract Number: 1943

The Prevalence of Anxiety and Depression in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1930

Thirty-Day Readmission Rate in Patients Who Were Initially Admitted for Active Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1927

Ultrasonographic Halo Score as a Marker for Diagnosis and Monitoring of Disease Activity in GCA

9:00AM-11:00AM: Abstract Number: 1925

Ultrasound Follow-up Examination of Intima-Media-Thickness of the Temporal and Axillary Artery over Six Months in Patients with Newly Diagnosed Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1929

Visual Ischemia During Relapse and Follow-up of Giant Cell Arteritis: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1934

What Is the Significance of Periarterial Temporal Small Vessel Inflammation (SVI) on Temporal Artery Biopsy (TAB) in the Diagnosis of Vasculitis? A Systematic Review and Meta-analysis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].